Regentis Biomaterials (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC, its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company's cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.
According to the company, GelrinC addresses a significant unmet need: approximately 470,000 cases for cartilage knee repair annually in the U.S. alone, where no off-the-shelf treatment is currently available. The European market similarly lacks convenient cell-free options, making the CE Mark approval a critical milestone. Regentis' Gelrin platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone. The implant is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process.
The training program at Humanitas Research Hospital in Milan is expected to set the stage for broader European adoption. Regentis plans to expand the initiative to other Centers of Excellence across Europe, ensuring that orthopedic surgeons gain hands-on experience with the implant technique. This approach mirrors successful commercialization strategies for other medical devices, where surgeon education is paramount to driving adoption.
The announcement underscores Regentis' commitment to bringing innovative tissue repair solutions to market. The company's focus on regenerative medicine aims to restore health and enhance quality of life, with GelrinC representing a potential paradigm shift in knee cartilage treatment. For further details, the full press release is available at https://ibn.fm/QOWWK.
Forward-looking statements in this release involve risks and uncertainties, as detailed in the company's SEC filings. Investors should not place undue reliance on these statements, which are based on information available as of the date hereof. The company undertakes no duty to update this information unless required by law.
